The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Metabolic and Haemostatic Effects of Estradiol Valerate/Dienogest, a Novel Oral Contraceptive: A Randomized, Open-Label, Single-Centre Study
Abstract
Background and objective The hormonal components of combined oral contraceptives (COCs) have various metabolic and haemostatic effects. The objective of this study was to compare the metabolic and haemostatic effects of a novel COC comprising estradiol valerate/dienogest (E(2)V/DNG) with ethinylestradiol/levonorgestrel (EE/LNG).Methods In a randomized, open-label study conducted in Germany over seven cycles, healthy women aged 18-50 years received E(2)V/DNG (E(2)V 3 mg on days 1-2, E(2)V 2 mg/DNG 2 mg on days 3-7, E(2)V 2 mg/DNG 3 mg on days 8-24, E(2)V 1 mg on days 25-26, placebo on days 27-28; n = 30) or EE/LNG (EE 0.03 mg/LNG 0.05 mg on days 1-6, EE 0.04 mg/LNG 0.075 mg on days 7-11, EE 0.03 mg/LNG 0.125 mg on days 12-21, placebo on days 22-28; n = 28). The primary variables were the mean intraindividual relative changes from baseline to cycle 7 in high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol levels. Changes in other lipid parameters, haemostatic parameters, sex hormone-binding globulin (SHBG), cortisol-binding globulin (CBG), carbohydrate metabolism parameters, blood pressure and body weight were also assessed.Results Mean ± SD HDL cholesterol increased by 7.9% ± 21.8% with E(2)V/DNG and decreased by 2.3% ± 14.4% with EE/LNG. Mean ± SD LDL cholesterol decreased by 6.5% ± 15.9% with E(2)V/DNG and by 3.0% ± 17.4% with EE/LNG. Mean ± SD prothrombin fragment 1 + 2 and D-dimer levels remained essentially unchanged in the E(2)V/DNG group (-0.6% ± 30.3% and -2.1% ± 43.5%, respectively), but increased in the EE/LNG group (by 117.3% ± 358.0% and 62.9% ± 99.5%, respectively). Changes in other hepatic-induced parameters (SHBG, CBG) and carbohydrate metabolism were generally less pronounced with E(2)V/DNG versus EE/LNG. Body weight and blood pressure remained stable throughout the study in both treatment groups. Both formulations were well tolerated, with no serious adverse events reported.Conclusion E(2)V/DNG had a minimal impact on metabolic and haemostatic parameters, and a more favourable effect than EE/LNG on lipid markers.Trial registration ClinicalTrials.gov Identifier: NCT00185224.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“New combinations containing E2, its ester estradiol valerate (EV), and estetrol (E4) have proven effective in combined contraceptives.”
From Ethinylestradiol in combined hormonal contraceptive has a broader effect on serum proteome compared with estradiol valerate: a randomized controlled trial (2023) · cites this paper as Junge et al., 2011
In the citing paper
“They induce good cycle control and provoke less marked changes in metabolic and endocrine parameters compared with EE”
From Ethinylestradiol in combined hormonal contraceptive has a broader effect on serum proteome compared with estradiol valerate: a randomized controlled trial (2023) · cites this paper as Junge et al., 2011
In the citing paper
“The lower impact of natural estrogens on hormone-binding globulins has also been observed comparing EV + DNG with EE + levonorgestrel (LNG) (Junge et al., 2011)”
From Ethinylestradiol in combined hormonal contraceptive has a broader effect on serum proteome compared with estradiol valerate: a randomized controlled trial (2023) · cites this paper as Junge et al., 2011
Citations
Cites
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Walsh, B. W., Schiff, I., Rosner, B., Greenberg, L., Ravnikar, V., & Sacks, F. M. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251702 · Cited by 1,152
Comparison of pharmacodynamic properties of various estrogen formulations
Mashchak, C. A., Lobo, R. A., Dozono-Takano, R., Eggena, P., Nakamura, R. M., Brenner, P. F., & Mishell, D. R. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(82)90218-6 · Cited by 316
Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
Páramo, J. A., Colucci, M., Collen, D., & de Werf, F. V. (1985) · BMJ · doi:10.1136/bmj.291.6495.573 · Cited by 302
Surrogate Endpoints And FDA’s Accelerated Approval Process
Fleming, T. R. (2005) · Health Affairs · doi:10.1377/hlthaff.24.1.67 · Cited by 252
Oelkers, W., Foidart, J. M., Dombrovicz, N., Welter, A., & Heithecker, R. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.6.7775629 · Cited by 247
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227
OOLOFESSON, B. O., Dahlén, G., & Nilsson, T. (1989) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059384 · Cited by 225
(BROWNE FJ),+BROWNE FJ: FRANCIS JAMES BROWNE.
Si, J., & Willis, A. T. (1963) · PubMed · Cited by 216
Toorians, A. W. F. T., Thomassen, S., Zweegman, S., Magdeleyns, E. J. P., Tans, G., Gooren, L. J., & Rosing, J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030520 · Cited by 207
Research works printed but not linked: 7
- Hirvonen, 1990, Advances Contraception, 6, 248
- Kivinen, 1996, Eur J Contracept Reprod Health Care, 1, 183
- Helgason, 1982 Suppl, Acta Obstet Gynecol Scand, 107, 1
- Oelkers, 1995 Jun, J Clin Endocrinol Metab, 80, 1816, 10.1210/jc.80.6.1816 · DOI
- Oettel, 1999, Drugs Today, 35, 3
- Parke, 2008, Obstet Gynecol, 111, 15S
- Parke, 2008, Eur J Contracept Reprod Health Care, 13, 94
Cited by
Sorted by citations
Sitruk-Ware, R., & Nath, A. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2012.09.004 · Cited by 247
Combination contraceptives: effects on weight
Gallo, M. F., Lopez, L. M., Grimes, D. A., Carayon, F., Schulz, K. F., & Helmerhorst, F. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003987.pub5 · Cited by 223
Stanczyk, F. Z., Archer, D. F., & Bhavnani, B. R. (2013) · Contraception · doi:10.1016/j.contraception.2012.12.011 · Cited by 201
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
Morimont, L., Haguet, H., Dogné, J., GASPARD, U. J., & Douxfils, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769187 · Cited by 186
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus
Lopez, L. M., Grimes, D. A., & Schulz, K. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006133.pub5 · Cited by 166
Metadata
- Authors
- Junge, W., Mellinger, U., Parke, S., & Serrani, M.
- Affiliations
- Bayer (Germany) (DE)
- Corresponding author
- Parke, Susanne
- Venue
- Clinical Drug Investigation
- Published
- 2011-08
- Volume
- 31
- Issue
- 8
- Pages
- 573-584
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- OpenAlex
- W194649371
- Cited by
- 107
- References
- 44
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 8 · 2021: 9 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 3 · 2014: 10 · 2013: 8 · 2012: 10
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- combined oral contraceptives, lipid metabolism, HDL cholesterol, LDL cholesterol, sex hormone-binding globulin, corticosteroid-binding globulin, carbohydrate metabolism, blood pressure, body weight, prothrombin fragment 1+2, D-dimer, hemostasis
- MeSH terms
- Adult, Contraceptives, Oral, Combined, Drug Combinations, Estradiol, Ethinyl Estradiol, Female, Glucose Tolerance Test, Hematologic Tests, Hemostasis, Humans, Lipids, Middle Aged, Nandrolone, Thyroid Function Tests, Treatment Outcome, Levonorgestrel, Carbohydrate Metabolism, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review